Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SDCBP | O00560 | 4/20 | 0.40 |
| ▸ | SDC2 | P34741 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 11/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30477302 | 1.00 | SDCBP (0.40) | SDCBPSDC2MAPK1CASP3NAMPT | |
| SCHEMBL25331706 | 0.88 | SDCBP (0.50) | SDCBPSDC2MAPK1CASP3 | |
| SCHEMBL30477296 | 0.88 | SDCBP (0.50) | SDCBPSDC2MAPK1CASP3 | |
| SCHEMBL25329776 | 0.86 | SDCBP (0.42) | SDCBPSDC2MAPK1CASP3EGFR | |
| SCHEMBL25330845 | 0.86 | SDCBP (0.41) | SDCBPSDC2MAPK1CASP3EGFR | |
| SCHEMBL30477286 | 0.86 | SDCBP (0.42) | SDCBPSDC2MAPK1CASP3EGFR | |
| SCHEMBL25332002 | 0.86 | MAPK1 (0.41) | SDCBPSDC2MAPK1 | |
| SCHEMBL25330087 | 0.86 | SDCBP (0.41) | SDCBPSDC2MAPK1CASP3EGFR | |
| SCHEMBL25330712 | 0.86 | SDCBP (0.42) | SDCBPSDC2MAPK1 | |
| SCHEMBL30477308 | 0.86 | SDCBP (0.42) | SDCBPSDC2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109135-A1 | NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS | INNOVO THERAPEUTICS INC. (KR) | 2025-04-03 | — | — | US | claimed |
| EP-4461726-A1 | NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS | Innovo Therapeutics Inc. (KR) | 2024-11-13 | — | — | EP | claimed |
| WO-2023132606-A1 | NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS | 주식회사 이노보테라퓨틱스 | 2023-07-13 | — | — | WO | claimed |
| US-20250109135-A1 | NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS | INNOVO THERAPEUTICS INC. (KR) | 2025-04-03 | — | — | US | disclosed |
| EP-4461726-A1 | NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS | Innovo Therapeutics Inc. (KR) | 2024-11-13 | — | — | EP | disclosed |
| WO-2023132606-A1 | NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS | 주식회사 이노보테라퓨틱스 | 2023-07-13 | — | — | WO | disclosed |
| WO-2023132606-A1 | NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS | 주식회사 이노보테라퓨틱스 | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109135-A1 | NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS | CASP1, CASP8, CASP2 | SDCBP 3595/4885SDC2 4311/4885MAPK1 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.